Implications of High Antifungal Susceptibility on *Schizophyllum commune*-Associated Allergy in Clinical Practice

Haruhiko Ogawa, a Masaki Fujimura, b Noriyuki Ohkura, c Koichi Makimura d

Division of Pulmonary Medicine, Ishikawa-ken, Saiseikai Kanazawa Hospital, Kanazawa, Japan; Respiratory Medicine, National Hospital Organization, Nanao Hospital, Nanao, Japan; Ishikawa Prefectural Central Hospital, Respiratory Medicine, Kanazawa, Japan; Laboratory of Space and Environmental Medicine, Teikyo University, Tokyo, Japan

Chowdary et al. reported that *Schizophyllum commune* is the predominant causative antigen of allergic bronchopulmonary mycosis (ABPM) (1). In a series of studies regarding *Schizophyllum* allergy in respiratory disease, they successfully demonstrated the in vitro profiles of the antifungal susceptibility of *S. commune* (2). Those studies raise questions regarding how the antifungal susceptibility should influence *Schizophyllum* allergy (3) in clinical practice.

(i) Would the high antifungal susceptibility of *S. commune* provide information for decision making with regard to the use of antifungal drugs for *S. commune* infection (4) or *Schizophyllum* allergy? The successful treatment of ABPM caused by *S. commune* (5) is assumed to consist of 4 strategies: (a) prevention and eradication of fungal colonization in the airway, (b) control of cosinophilic bronchitis caused by fungal exposure, (c) removal of any mucus plugs from the airway, and (d) effective management of environmental fungi. This management process is applicable to various types of *Schizophyllum* allergies in respiratory disease (6). However, further investigations are required to clarify whether full doses of antifungal drugs are actually necessary to eradicate fungal colonization in the airways under such conditions. On the other hand, how should we plan antifungal therapy in patients with severe asthma with fungal sensitization (7) or in patients with *S. commune* infection?

(ii) Does the high antifungal susceptibility of *S. commune* have advantages with regard to the recurrence of ABPM caused by this fungus? Chowdhary et al. discussed the outcomes of antifungal treatment in 11 cases. In addition, they reported that the 5 of 8 cases of ABPM treated with itraconazole (ITCZ) showed no recrudescence after 6 to 24 months of follow-up. Dealing with this fungus as a spore overgrowth season in the field.

The results of the study of Chowdhary et al. encourage future work by clinicians dealing with *S. commune* allergy (8–10). Periodic surveys of *S. commune* and the appropriate use of antifungal drugs may be useful for establishing strategies to prevent disease recurrence.

ACKNOWLEDGMENTS

H. Ogawa, N. Ohkura, and K. Makimura belong to the Fungus-Associated Cough Research Society. K. Makimura especially contributes to the identification of fungi. M. Fujimura is the general conductor of this study.

We declare that we have no competing interests that might be perceived to influence the results and discussion reported in the present paper.

REFERENCES


